scholarly journals Nanoparticle‐mediated siRNA delivery systems for cancer therapy

View ◽  
2021 ◽  
pp. 20200111
Author(s):  
Han Gao ◽  
Ruoyu Cheng ◽  
Hélder A. Santos
Keyword(s):  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems

Black phosphorus quantum dot based novel siRNA delivery systems in human pluripotent teratoma PA-1 cells

2017 ◽  
Vol 5 (27) ◽  
pp. 5433-5440 ◽  
Author(s):  
Feng Yin ◽  
Kuan Hu ◽  
Si Chen ◽  
Dongyuan Wang ◽  
Jianing Zhang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Quantum Dot ◽  
Transfection Efficiency ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Black Phosphorus ◽  
Semiconducting Materials ◽  
Photothermal Effects ◽  
Low Cytotoxicity

As a novel semiconducting materials, BP-QDs possess superior transfection efficiency, excellent biocompatibility and low cytotoxicity, which shows promising potential for siRNA delivery and photothermal effects in cancer therapy.

scholarly journals Non‐viral siRNA delivery systems for pancreatic cancer therapy

2021 ◽  
Author(s):  
Shahin Aghamiri ◽  
Pourya Raee ◽  
Sam Talaei ◽  
Samira Mohammadi‐Yeganeh ◽  
Shiva Bayat ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Pancreatic Cancer Therapy

scholarly journals Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Molecules ◽  
2020 ◽  
Vol 25 (11) ◽  
pp. 2692 ◽  
Author(s):  
Francesco Mainini ◽  
Michael R. Eccles
Keyword(s):  
Cancer Therapy ◽  
Gene Silencing ◽  
Sirna Delivery ◽  
Cancer Therapeutics ◽  
Delivery Systems ◽  
Fine Tuning ◽  
Host Cells ◽  
Specific Cell ◽  
Small Interfering Rnas

RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve efficient delivery of siRNAs into cells in vivo, including into tumor and/or host cells in the tumor micro-environment (TME). Consequently, lipid and polymer-based nanoparticle siRNA delivery systems have been developed to surmount these physiological barriers. In this article, we review the strategies that have been developed to facilitate siRNA survival in the circulatory system, siRNA movement from the blood into tissues and the TME, targeted siRNA delivery to the tumor or specific cell types, cellular uptake, and escape from endosomal degradation. We also discuss the use of various types of lipid and polymer-based carriers for cancer therapy, including a section on anti-tumor nanovaccines enhanced by siRNAs. Finally, we review current and recent clinical trials using NPs loaded with siRNAs for cancer therapy. The siRNA cancer therapeutics field is rapidly evolving, and it is conceivable that precision cancer therapy could, in the relatively near future, benefit from the combined use of cancer therapies, for example immune checkpoint blockade together with gene-targeting siRNAs, personalized for enhancing and fine-tuning a patient’s therapeutic response.

Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy

2021 ◽  
Vol 260 ◽  
pp. 117809
Author(s):  
Milad Ashrafizadeh ◽  
Masoud Delfi ◽  
Farid Hashemi ◽  
Amirhossein Zabolian ◽  
Hossein Saleki ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Biomedical Application ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Potential Usefulness

scholarly journals siRNA Delivery Technology for Cancer Therapy: Promise and Challenges

2019 ◽  
Author(s):  
Fateme Karimi Dermani ◽  
Farid Azizi Jalilian ◽  
Hossein Hossienkhani ◽  
Razieh Ezati ◽  
Razieh Amini
Keyword(s):  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Therapeutic Interventions ◽  
Great Promise ◽  
Specific Gene ◽  
Small Interfering Rnas ◽  
Systemic Delivery ◽  
New Class ◽  
Delivery Technology

Abstract- Small interfering RNAs (siRNA) technology has shown great promise as a new class of therapeutic interventions for the treatment of cancer and other diseases. It is a remarkable endogenous pathway that can regulate sequence-specific gene silencing. Despite the excitement about possible applications of this biological process for sequence-specific gene regulation, the major limitations against the use of siRNA-based therapeutics are their rapid degradation by serum nuclease, poor cellular uptake, and rapid renal clearance following systemic delivery, off-target effects and the induction of immune responses. Many researchers have tried to overcome these limitations by developing nuclease-resistant chemically-modified siRNAs and a variety of synthetic and natural biodegradable lipids and polymers to enhance the efficacy and safety profiles of siRNA delivery. Ideal siRNA-based delivery systems for cancer therapy must be clinically suitable, safe and effective. In this review, we introduce the greatest challenges in achieving efficient RNAi delivery and discuss design criteria and various delivery strategies for cancer therapy, including chemical modifications, lipid-based nano-vectors, polymer-mediated delivery systems, conjugate delivery systems, and others.

scholarly journals Non-viral siRNA delivery systems for pancreatic cancer therapy

2020 ◽  
Author(s):  
Shahin aghamiri ◽  
Alireza Teymouri ◽  
Samira Mohammadi Yeganeh ◽  
Shiva Bayat ◽  
Delsuz Rezaee ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Sirna Delivery ◽  
Delivery Systems ◽  
Pancreatic Cancer Therapy

Lipid-based siRNA Delivery Systems

2012 ◽  
Vol 39 (5) ◽  
pp. 396-401 ◽  
Author(s):  
Wen-Juan DONG ◽  
Yin-Jian ZHOU ◽  
Wei LIANG
Keyword(s):  
Sirna Delivery ◽  
Delivery Systems

Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy

2020 ◽  
Vol 21 (11) ◽  
pp. 1084-1098
Author(s):  
Fengqian Chen ◽  
Yunzhen Shi ◽  
Jinming Zhang ◽  
Qi Liu
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Therapeutic Index ◽  
Delivery Systems ◽  
Epigenetic Therapy ◽  
Cancer Therapies ◽  
Therapeutic Benefits ◽  
High Therapeutic Index

This review summarizes the epigenetic mechanisms of deoxyribonucleic acid (DNA) methylation, histone modifications in cancer and the epigenetic modifications in cancer therapy. Due to their undesired side effects, the use of epigenetic drugs as chemo-drugs in cancer therapies is limited. The drug delivery system opens a door for minimizing these side effects and achieving greater therapeutic benefits. The limitations of current epigenetic therapies in clinical cancer treatment and the advantages of using drug delivery systems for epigenetic agents are also discussed. Combining drug delivery systems with epigenetic therapy is a promising approach to reaching a high therapeutic index and minimizing the side effects.

Sign in / Sign up

Export Citation Format

Share Document